1
|
Peyrin-Biroulet L, Bossuyt P, Bettenworth D, Loftus EV, Anjie SI, D'Haens G, Saruta M, Arkkila P, Park H, Choi D, Kim DH, Reinisch W. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis. Dig Dis Sci 2024; 69:1808-1825. [PMID: 38499736 PMCID: PMC11098872 DOI: 10.1007/s10620-023-08252-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Accepted: 12/14/2023] [Indexed: 03/20/2024]
Abstract
BACKGROUND Infliximab and vedolizumab are widely used to treat Crohn's disease (CD) and ulcerative colitis (UC). AIMS This systematic review and network meta-analysis evaluated comparative efficacy of various regimens for intravenous or subcutaneous infliximab and vedolizumab during maintenance treatment in CD and UC. METHODS Parallel-group randomized controlled trials (RCTs) were identified by a systematic literature review (CRD42022383401) and included if they evaluated therapeutics of interest for maintenance treatment of adults with moderate-to-severe luminal CD or UC and assessed clinical remission between Weeks 30 and 60. Clinical remission rates in CD or UC and mucosal healing rates in UC were analyzed in a Bayesian network meta-analysis model. Endoscopic outcomes in CD were synthesized by proportional meta-analysis. RESULTS Overall, 13 RCTs were included in the analyses. All vedolizumab studies randomized induction responders to maintenance treatment; infliximab studies used a treat-through design. Subcutaneous infliximab 120 mg every 2 weeks had the highest odds ratio (OR) [95% credible interval] versus placebo for clinical remission during the maintenance phase (CD: 5.90 [1.90-18.2]; UC: 5.45 [1.94-15.3]), with surface under the cumulative ranking curve (SUCRA) values of 0.91 and 0.82, respectively. For mucosal healing in UC, subcutaneous infliximab 120 mg every 2 weeks showed the highest OR (4.90 [1.63-14.1]), with SUCRA value of 0.73, followed by intravenous vedolizumab 300 mg every 4 weeks (SUCRA value, 0.70). Endoscopic outcomes in CD were better with subcutaneous infliximab 120 mg every 2 weeks than intravenous infliximab 5 mg/kg every 8 weeks. CONCLUSIONS Subcutaneous infliximab showed a favorable efficacy profile for achieving clinical remission and endoscopic outcomes during maintenance treatment in CD or UC.
Collapse
Affiliation(s)
- L Peyrin-Biroulet
- Department of Gastroenterology, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France
| | - P Bossuyt
- Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium
| | - D Bettenworth
- Medical Faculty of the University of Münster, Münster, North Rhine-Westphalia, Germany
- CED Schwerpunktpraxis Münster, Münster, North Rhine-Westphalia, Germany
| | - E V Loftus
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
| | - S I Anjie
- Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - G D'Haens
- Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - M Saruta
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
| | - P Arkkila
- Department of Gastroenterology, Helsinki University and Helsinki University Hospital, Helsinki, Finland
| | - H Park
- Medical Department, Celltrion Healthcare Co., Ltd, Incheon, Republic of Korea
- Global Medical Department, Celltrion Inc, Incheon, Republic of Korea
| | - D Choi
- Medical Department, Celltrion Healthcare Co., Ltd, Incheon, Republic of Korea
- Global Medical Department, Celltrion Inc, Incheon, Republic of Korea
| | - D- H Kim
- Medical Department, Celltrion Healthcare Co., Ltd, Incheon, Republic of Korea
- Global Medical Department, Celltrion Inc, Incheon, Republic of Korea
| | - W Reinisch
- Department of Internal Medicine III, Medical University of Vienna, 1090, Vienna, Austria.
| |
Collapse
|
2
|
Lee E, Zhang Z, Chen CC, Choi D, Rivera ACA, Linton E, Ho YJ, Love J, LaClair J, Wongvipat J, Sawyers CL. Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer. bioRxiv 2024:2024.03.18.585532. [PMID: 38562884 PMCID: PMC10983989 DOI: 10.1101/2024.03.18.585532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
There is optimism that cancer drug resistance can be addressed through appropriate combination therapy, but success requires understanding the growing complexity of resistance mechanisms, including the evolution and population dynamics of drug-sensitive and drug-resistant clones over time. Using DNA barcoding to trace individual prostate tumor cells in vivo , we find that the evolutionary path to acquired resistance to androgen receptor signaling inhibition (ARSI) is dependent on the timing of treatment. In established tumors, resistance occurs through polyclonal adaptation of drug-sensitive clones, despite the presence of rare subclones with known, pre-existing ARSI resistance. Conversely, in an experimental setting designed to mimic minimal residual disease, resistance occurs through outgrowth of pre-existing resistant clones and not by adaptation. Despite these different evolutionary paths, the underlying mechanisms responsible for resistance are shared across the two evolutionary paths. Furthermore, mixing experiments reveal that the evolutionary path to adaptive resistance requires cooperativity between subclones. Thus, despite the presence of pre-existing ARSI-resistant subclones, acquired resistance in established tumors occurs primarily through cooperative, polyclonal adaptation of drug-sensitive cells. This tumor ecosystem model of resistance has new implications for developing effective combination therapy.
Collapse
|
3
|
Choi D, Choi SH, Jung H, Kim J. CT findings of inferior vena cava trauma according to the level of injury: a retrospective analysis of 19 cases in a single trauma centre. Clin Radiol 2024; 79:e182-e188. [PMID: 37925364 DOI: 10.1016/j.crad.2023.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 09/29/2023] [Accepted: 10/05/2023] [Indexed: 11/06/2023]
Abstract
AIM To analyse the clinicoradiological characteristics of traumatic inferior vena cava (IVC) injury level on preoperative computed tomography (CT). MATERIALS AND METHODS This retrospective study evaluated patients from a single trauma centre treated for traumatic IVC injury between January 2014 and January 2021. Data on demographics, mechanism of injury, Injury Severity Score, radiological findings on CT and angiography, IVC injury level in surgical findings, complications, and clinical outcomes were collected. RESULTS During the 8-year study period, 36 patients presented with traumatic IVC injury: 19 underwent preoperative CT with 17 (89%) blunt and two (11%) penetrating injuries. The most common primary CT sign was contour abnormality (53%, n=10), followed by intraluminal flap and active extravasation (21%, n=4). Among the secondary signs, hepatic laceration (53%, n=10) and retroperitoneal haemorrhage (53%, n=10) were the most common. Frequencies of primary and secondary signs were higher in the infrarenal and suprarenal than in the retrohepatic vena cava injuries. Diagnostic capability of preoperative CT for IVC injury differed according to the IVC level. The detection rate was the highest for an infrarenal vena cava injury at 100% (n=4), followed by that for a suprarenal, suprahepatic, and retrohepatic vena cava injuries at 75% (n=3), 43% (n=3), and 25% (n=1), respectively. CONCLUSION CT findings of traumatic IVC injuries may vary depending on the mechanism and anatomical site of injury. Familiarity with IVC injury imaging features may help in diagnosis and surgical treatment planning.
Collapse
Affiliation(s)
- D Choi
- Division of Trauma Surgery, Department of Surgery, Ajou University School of Medicine, Republic of Korea
| | - S H Choi
- Division of Trauma Surgery, Department of Surgery, Ajou University School of Medicine, Republic of Korea
| | - H Jung
- Division of Trauma Surgery, Department of Surgery, Ajou University School of Medicine, Republic of Korea
| | - J Kim
- Department of Radiology, Ajou University School of Medicine, Republic of Korea.
| |
Collapse
|
4
|
Kim M, Lee JH, Choi D, Kwon J. Is The Modified Nutrition Risk In The Critically Ill(mNUTRIC) Score A Useful Method For Screening Traumatic Icu Patients? Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
5
|
Koo Y, Yun T, Chae Y, Lee D, Choi D, Oh J, Kim J, Kim H, Yang MP, Kang BT. Suspected human intravenous immunoglobulin-induced acute haemolytic anaemia in a dog. J Small Anim Pract 2021; 63:482-485. [PMID: 34874062 DOI: 10.1111/jsap.13449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 10/18/2021] [Accepted: 10/31/2021] [Indexed: 11/28/2022]
Abstract
A 2-year-old mixed breed dog presented with a 1-year history of crust and erosion on the nasal planum. Because histopathological examination revealed ruptured intraepidermal pustules and superficial dermal inflammation, the dog was diagnosed with pemphigus foliaceus. Human intravenous immunoglobulin was administered in two consecutive doses of 0.5 g/kg/day due to poor therapeutic response to previous immunosuppressive therapy. From Day 3 after the first dose of human intravenous immunoglobulin, tachypnoea, pale mucous membrane, haemoglobinuria and haemoglobinemia were observed, thus confirming haemolytic anaemia. Other drug-induced haemolytic anaemias were excluded because no additional drugs had been administered before the haemolysis occurred. Immune-mediated haemolytic anaemia was also excluded because the direct antiglobulin test was negative. Two transfusions were performed, and haemolysis was not observed from Day 4 of haemolytic anaemia onset. In conclusion, human intravenous immunoglobulin-induced haemolytic anaemia should be considered in dogs that develop haemolysis following the administration of human intravenous immunoglobulin.
Collapse
Affiliation(s)
- Y Koo
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - T Yun
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - Y Chae
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - D Lee
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - D Choi
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - J Oh
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - J Kim
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - H Kim
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - M P Yang
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - B T Kang
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| |
Collapse
|
6
|
Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen HA, de Stanchina E, Sawyers C, Rosen N, Hsieh AC, Chen Y, Carver BS. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nat Commun 2021; 12:5053. [PMID: 34417459 PMCID: PMC8379232 DOI: 10.1038/s41467-021-25341-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 08/05/2021] [Indexed: 12/30/2022] Open
Abstract
Previous studies have suggested that PTEN loss is associated with p110β signaling dependency, leading to the clinical development of p110β-selective inhibitors. Here we use a panel pre-clinical models to reveal that PI3K isoform dependency is not governed by loss of PTEN and is impacted by feedback inhibition and concurrent PIK3CA/PIK3CB alterations. Furthermore, while pan-PI3K inhibition in PTEN-deficient tumors is efficacious, upregulation of Insulin Like Growth Factor 1 Receptor (IGF1R) promotes resistance. Importantly, we show that this resistance can be overcome through targeting AKT and we find that AKT inhibitors are superior to pan-PI3K inhibition in the context of PTEN loss. However, in the presence of wild-type PTEN and PIK3CA-activating mutations, p110α-dependent signaling is dominant and selectively inhibiting p110α is therapeutically superior to AKT inhibition. These discoveries reveal a more nuanced understanding of PI3K isoform dependency and unveil novel strategies to selectively target PI3K signaling nodes in a context-specific manner. Understanding the mechanisms driving PI3K isoform dependency in prostate cancer can help the design of future clinical trials. Here, the authors show that gain-of-function mutations in PIK3CA or PIK3CB can confer PI3K p110 isoform dependency and that the direct inhibition of AKT may be superior to PI3K inhibition in PTEN-deficient prostate cancers.
Collapse
Affiliation(s)
- Ninghui Mao
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Zeda Zhang
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Young Sun Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Danielle Choi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Aura Agudelo Rivera
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Dan Li
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Cindy Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Samuel Haywood
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Xiaoping Chen
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
| | - Qing Chang
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
| | - Guotai Xu
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Hsuan-An Chen
- Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Elisa de Stanchina
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
| | - Charles Sawyers
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Neal Rosen
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Andrew C Hsieh
- Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Yu Chen
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Brett S Carver
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .,Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
| |
Collapse
|
7
|
Feng W, Cao Z, Lim PX, Zhao H, Luo H, Mao N, Lee YS, Rivera AA, Choi D, Wu C, Han T, Romero R, de Stanchina E, Carver BS, Wang Q, Jasin M, Sawyers CL. Rapid interrogation of cancer cell of origin through CRISPR editing. Proc Natl Acad Sci U S A 2021; 118:e2110344118. [PMID: 34353917 PMCID: PMC8364185 DOI: 10.1073/pnas.2110344118] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The increasing complexity of different cell types revealed by single-cell analysis of tissues presents challenges in efficiently elucidating their functions. Here we show, using prostate as a model tissue, that primary organoids and freshly isolated epithelial cells can be CRISPR edited ex vivo using Cas9-sgRNA (guide RNA) ribotnucleoprotein complex technology, then orthotopically transferred in vivo into immunocompetent or immunodeficient mice to generate cancer models with phenotypes resembling those seen in traditional genetically engineered mouse models. Large intrachromosomal (∼2 Mb) or multigenic deletions can be engineered efficiently without the need for selection, including in isolated subpopulations to address cell-of-origin questions.
Collapse
Affiliation(s)
- Weiran Feng
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Zhen Cao
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
- Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10021
| | - Pei Xin Lim
- Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Huiyong Zhao
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Hanzhi Luo
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Ninghui Mao
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Young Sun Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Aura Agudelo Rivera
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Danielle Choi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Chao Wu
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Teng Han
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Rodrigo Romero
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Elisa de Stanchina
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Brett S Carver
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065
- Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Qiao Wang
- Key Laboratory of Medical Molecular Virology of Ministry of Education/National Health Commission/Chinese Academy of Medical Sciences, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, China
| | - Maria Jasin
- Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| | - Charles L Sawyers
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065;
- HHMI, Memorial Sloan Kettering Cancer Center, New York, NY 10065
| |
Collapse
|
8
|
Knopf J, Lee S, Bulsara K, Moss I, Choi D, Onyiuke H. Onyiuke Grading Scale: A clinical classification system for the diagnosis and management of Bertolotti syndrome. Neurochirurgie 2021; 67:540-546. [PMID: 34051248 DOI: 10.1016/j.neuchi.2021.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 03/29/2021] [Accepted: 05/09/2021] [Indexed: 11/17/2022]
Abstract
BACKGROUND Lumbosacral transitional vertebrae (LSTV) is a common anatomic variant of the spine, characterized by the formation of a pseudoarticulation between the transverse process of the lumbar vertebrae and sacrum or ilium. LSTVs have been implicated as a potential source of low back pain - dubbed Bertolotti syndrome. Traditionally, LSTVs have only been subdivided into types I-IV based on the Castellvi radiographic classification system. OBJECTIVE Solely identifying the type of LSTV radiographically provides no clinical relevance to the treatment of Bertolotti syndrome. Here, we seek to analyze such patients and identify a clinical grading scale and diagnostic-therapeutic algorithm to optimize care for patients with this congenital anomaly. METHODS Patients presenting with back pain between 2011 and 2018 attributable to a lumbosacral transitional vertebra were identified retrospectively. Data was collected from these patients' charts regarding demographic information, clinical presentation, diagnostic imaging, treatment and outcomes. Based on evaluation of these cases and review of the literature, a diagnostic-therapeutic algorithm is proposed. RESULTS Based on our experiences evaluating and treating these patients and review of the existing literature, we propose a clinical classification system for Bertolotti syndrome: we proposed a 4-grade scale for patients with Bertolotti syndrome based upon location, severity, and characteristics of pain experienced due to LSTVs. CONCLUSION Based on our experience with the cases illustrated here, we recommend managing patients with LSTV based on our diagnostic-therapeutic algorithm. Moving forward, a larger prospective study with a larger patient cohort is needed to further validate the treatment paradigm.
Collapse
Affiliation(s)
- J Knopf
- University of Connecticut School of Medicine, Farmington, CT, USA.
| | - S Lee
- University of Connecticut School of Medicine, Farmington, CT, USA
| | - K Bulsara
- Department of Neurosurgery, UConn Health, Farmington, CT, USA
| | - I Moss
- Department of Orthopedic Surgery, UConn Health, Farmington, CT, USA
| | - D Choi
- Department of Neurosurgery, UConn Health, Farmington, CT, USA
| | - H Onyiuke
- Department of Neurosurgery, UConn Health, Farmington, CT, USA
| |
Collapse
|
9
|
Bhushan A, Choi D, Maresh G, Deodhar A. Correction to: Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience. Rheumatol Int 2021; 42:493. [PMID: 33903965 DOI: 10.1007/s00296-021-04870-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- A Bhushan
- Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
| | - D Choi
- Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.,Graduate School of Dentistry, Kyung Hee University, Seoul, Korea
| | - G Maresh
- Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
| | - A Deodhar
- Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
| |
Collapse
|
10
|
Agusto M, Salman A, Parker D, Choi D, Schincaglia GP. Root Coverage Predictability in the Treatment of Gingival Recessions on Mandibular Anterior Teeth. JDR Clin Trans Res 2021; 7:224-233. [PMID: 33899565 DOI: 10.1177/23800844211009437] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
INTRODUCTION Mandibular anterior teeth are most frequently affected by gingival recession. However, data regarding mucogingival treatment aimed at root coverage in this specific location are limited. OBJECTIVE The purpose of this study was to systematically review the scientific literature and to use the meta-analytic approach to address the following focused question: "What is the effectiveness of different surgical approaches on clinical and patient-related outcomes in the treatment of buccal gingival recessions on mandibular anterior teeth?" METHODS Studies were located by searching 3 electronic databases (Medline, Scopus, and Cochrane databases) and cross-referencing. Randomized and nonrandomized studies including at least 1 arm involving the use of pedicle flaps and/or free soft tissue grafts in the treatment of gingival recessions (recession type [RT] 1 and RT2) located on the buccal aspects of mandibular centrals, laterals and canines, were included in the analysis. Primary outcome was mean root coverage (mRC), expressed in percentage, based on a 3- to 12-mo follow-up observation. A Bayesian single-arm network meta-analysis was performed to identify a treatment hierarchy of the different surgical techniques. RESULTS Sixteen studies, with a total of 23 arms, were included in the quantitative analysis. The greatest mRC is associated with laterally positioned flap (LPF) + connective tissue graft (CTG) (91.2%) and tunnel (TUN) + CTG (89.4%), whereas LPF alone, coronally advanced flap (CAF) + CTG, and free gingival graft (FGG) showed lower mRC (79.1%, 78.9%, and 68.5% respectively). TUN + CTG provides significantly greater mRC compared to CAF+CTG. No difference among the procedures could be observed in terms of keratinized tissue width gain. CONCLUSIONS Treatment hierarchy generated by an arm-based network meta-analysis model suggested that tunnel and laterally positioned flap, both in combination with connective tissue graft, may provide the greatest mean root coverage in the treatment of mandibular anterior recessions. KNOWLEDGE TRANSFER STATEMENT The results of the present systematic review can be used by clinicians when deciding which approach to adopt when treating buccal gingival recessions on mandibular anterior teeth. In particular, procedures based on a laterally positioned flap or a tunneling technique, both in combination with connective tissue graft, seem to be the most predictable therapeutic decision.
Collapse
Affiliation(s)
- M Agusto
- Department of Periodontics, School of Dentistry, West Virginia University, Morgantown, WV, USA
| | - A Salman
- Department of Periodontics, School of Dentistry, West Virginia University, Morgantown, WV, USA
| | - D Parker
- Division of Population Health Sciences, University of Alaska Anchorage, Anchorage, AK, USA
| | - D Choi
- Department of Periodontics, School of Dentistry, West Virginia University, Morgantown, WV, USA
| | - G P Schincaglia
- Department of Periodontics, School of Dentistry, West Virginia University, Morgantown, WV, USA.,School of Dentistry, University of Ferrara, Ferrara, Italy
| |
Collapse
|
11
|
Bhushan A, Choi D, Maresh G, Deodhar A. Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience. Rheumatol Int 2021; 42:485-492. [PMID: 33782747 DOI: 10.1007/s00296-021-04842-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Accepted: 03/10/2021] [Indexed: 11/27/2022]
Abstract
Diffuse alveolar hemorrhage (DAH) is a rare but potentially life-threatening emergency that has both immune and non-immune etiologies. The objective of this investigation was to compare the risk factors and outcomes of immune and non-immune causes of DAH at a tertiary-care academic center. This was a retrospective observational study conducted at a University center. We reviewed all chest radiographs spanning 12 years (2007-2019) at our institute with the words "diffuse alveolar hemorrhage" in the body of their report, and ascertained cases of DAH through a detailed chart review. We used Chi-squared test to determine the differences in risk factors and outcomes between immune versus non-immune causes of DAH. We performed logistic regressions to assess whether baseline demographics and clinical features influence four critical outcomes: death, shock, renal failure, and severe anemia requiring transfusions. Over the 12-year period, there were 88 patients with DAH, 55 with non-immune and 33 with immune etiologies. Among immune causes of DAH, granulomatosis with polyangiitis (GPA) (10.2%), microscopic polyangiitis (MPA) (9%) and systemic lupus erythematosus (SLE) (9%) were most common. Among non-immune causes of DAH, coagulopathy (6.8%), decompensated heart failure (4.5%) and infection (3.4%) were most common. Patients with non-immune causes of DAH were 45.8% more likely to die and 20.7% less likely to experience sustained remission (p = 0.001). Patient with immune causes of DAH were 21% more likely to have extra-pulmonary findings and 23.7% more likely to have received hemodialysis (HD). The presence of extra-pulmonary findings was statistically significantly correlated with the number of blood products received, the need for HD and non-statistically significantly correlated with likelihood of death. Patients with immune causes of DAH were 71.5% more likely to receive multimodal therapy including corticosteroids. Immune-mediated DAH is associated with a better prognosis than non-immune DAH, despite its greater association with extra-pulmonary findings and requirement for hemodialysis.
Collapse
Affiliation(s)
- A Bhushan
- Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
| | - D Choi
- Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.,Graduate School of Dentistry, Kyung Hee University, Seoul, Korea
| | - G Maresh
- Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
| | - A Deodhar
- Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
| |
Collapse
|
12
|
Cho JM, Yoon YJ, Lee S, Kim D, Choi D, Kim J, Lim JY. Retroductal Delivery of Epidermal Growth Factor Protects Salivary Progenitors after Irradiation. J Dent Res 2021; 100:883-890. [PMID: 33754871 DOI: 10.1177/0022034521999298] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Salivary gland hypofunction after irradiation is associated with a deficit of epithelial stem/progenitors in salivary glands. Although epidermal growth factor (EGF) is known to stimulate the proliferation of epithelial cells, the therapeutic effect of EGF on salivary epithelial stem/progenitors remains undetermined. In this study, we administered EGF to submandibular glands (SMGs) via a retrograde route through the SMG excretory duct before fractionated irradiation and examined whether EGF could protect salivary epithelial progenitor cells from radiation and alleviate radiation-induced salivary hypofunction. EGF-treated mice exhibited greater body and gland weights at 12 wk after irradiation than untreated mice. The retroductal delivery of EGF improved salivary secretory function and increased salivary amylase activity in a dose-dependent manner. Histological examinations highlighted the amelioration of the loss of keratine-14+ (KRT14+) basal ductal and/or MIST1+ acinar cells, as well as induction of fibrosis, following irradiation in EGF-treated mice. An additional in vitro experiment using a salivary gland organoid irradiation model indicated that the radioprotective effects of EGF promoted the growth and inhibited the apoptotic cell death of salivary epithelial cells. Our results suggest that retroductal delivery of EGF may be a promising therapeutic option for preventing radiation-induced salivary gland hypofunction.
Collapse
Affiliation(s)
- J M Cho
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Y J Yoon
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - S Lee
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - D Kim
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - D Choi
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - J Kim
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - J Y Lim
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
13
|
Park CJ, Han K, Kim H, Ahn SS, Choi D, Park YW, Chang JH, Kim SH, Cha S, Lee SK. MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas. AJNR Am J Neuroradiol 2021; 42:448-456. [PMID: 33509914 DOI: 10.3174/ajnr.a6983] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 10/19/2020] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND PURPOSE Isocitrate dehydrogenase (IDH) wild-type lower-grade gliomas (histologic grades II and III) with epidermal growth factor receptor (EGFR) amplification or telomerase reverse transcriptase (TERT) promoter mutation are reported to behave similar to glioblastoma. We aimed to evaluate whether MR imaging features could identify a subset of IDH wild-type lower-grade gliomas that carry molecular features of glioblastoma. MATERIALS AND METHODS In this multi-institutional retrospective study, pathologically confirmed IDH wild-type lower-grade gliomas from 2 tertiary institutions and The Cancer Genome Atlas constituted the training set (institution 1 and The Cancer Genome Atlas, 64 patients) and the independent test set (institution 2, 57 patients). Preoperative MRIs were analyzed using the Visually AcceSAble Rembrandt Images and radiomics. The molecular glioblastoma status was determined on the basis of the presence of EGFR amplification and TERT promoter mutation. Molecular glioblastoma was present in 73.4% and 56.1% in the training and test sets, respectively. Models using clinical, Visually AcceSAble Rembrandt Images, and radiomic features were built to predict the molecular glioblastoma status in the training set; then they were validated in the test set. RESULTS In the test set, a model using both Visually AcceSAble Rembrandt Images and radiomic features showed superior predictive performance (area under the curve = 0.854) than that with only clinical features or Visually AcceSAble Rembrandt Images (areas under the curve = 0.514 and 0.648, respectively; P < . 001, both). When both Visually AcceSAble Rembrandt Images and radiomics were added to clinical features, the predictive performance significantly increased (areas under the curve = 0.514 versus 0.863, P < .001). CONCLUSIONS MR imaging features integrated with machine learning classifiers may predict a subset of IDH wild-type lower-grade gliomas that carry molecular features of glioblastoma.
Collapse
Affiliation(s)
- C J Park
- From the Department of Radiology (C.J.P.), Yonsei University College of Medicine, Seoul, Korea
| | - K Han
- Department of Radiology (K.H., H.K., S.S.A., Y.W.P., S.-K.L.), Research Institute of Radiological Sciences, Center for Clinical Imaging Data Science
| | - H Kim
- Department of Radiology (K.H., H.K., S.S.A., Y.W.P., S.-K.L.), Research Institute of Radiological Sciences, Center for Clinical Imaging Data Science
| | - S S Ahn
- Department of Radiology (K.H., H.K., S.S.A., Y.W.P., S.-K.L.), Research Institute of Radiological Sciences, Center for Clinical Imaging Data Science
| | - D Choi
- Department of Computer Science (D.C.), Yonsei University, Seoul, Korea
| | - Y W Park
- Department of Radiology (K.H., H.K., S.S.A., Y.W.P., S.-K.L.), Research Institute of Radiological Sciences, Center for Clinical Imaging Data Science
| | | | - S H Kim
- Department of Pathology (S.H.K.), Yonsei University College of Medicine, Seoul, Korea
| | - S Cha
- Department of Radiology and Biomedical Imaging (S.C.), University of California San Francisco, San Francisco, California
| | - S-K Lee
- Department of Radiology (K.H., H.K., S.S.A., Y.W.P., S.-K.L.), Research Institute of Radiological Sciences, Center for Clinical Imaging Data Science
| |
Collapse
|
14
|
Inohara T, Alfadhel M, Choi D, Starovoytov A, Saw J. Coronary angiographic manifestations of fibromuscular dysplasia and clinical outcomes in patients with spontaneous coronary artery dissection. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Fibromuscular dysplasia (FMD) is a common predisposing condition for spontaneous coronary artery dissection (SCAD), which is an important cause of myocardial infarction (MI) in young to middle-aged women. However, its impact on clinical presentation, coronary anatomies, and outcomes have not been reported.
Purpose
To evaluate coronary angiographic characteristics and clinical outcomes in SCAD patients with or without underlying extracoronary FMD.
Methods
We retrospectively analyzed patients enrolled in our Vancouver SCAD registries who were screened for extracoronary FMD. Extracoronary FMD was defined as the presence of multifocal FMD on catheter or noninvasive angiography (computed tomographic or magnetic resonance imaging) in ≥1 extracoronary vascular beds. We reviewed coronary angiograms for manifestations of coronary FMD that were previously described (i.e. irregular stenosis, smooth stenosis, dilatation/ectasia, and tortuosity). Severe tortuosity was defined as ≥2 consecutive bends ≥180° at any cardiac cycle or 360° loop in ≥1 epicardial artery that was ≥2 mm in diameter. Clinical outcomes of major adverse cardiovascular event (MACE), a composite of all-cause death, MI, and stroke, were evaluated.
Results
We included 346 SCAD patients, 250 (72.3%) had extracoronary FMD. Patients with FMD were older (54.6±9.5 vs. 51.7±9.8 years) and more likely to have prior history of MI (7.2% vs. 1.0%, p=0.047) and stroke (4.4% vs. 0%, p=0.081) compared with non-FMD patients. The proportion of multivessel SCAD and TIMI flow was not different between groups, but type 3 SCAD was more commonly observed in FMD group (11.6% vs. 3.1%, p=0.026). On coronary angiography, severe tortuosity was more prevalent in patients with extracoronary FMD (58.4% vs. 36.5%, p<0.001), whereas rates of irregular stenosis, smooth stenosis, and dilatation/ectasia were not significantly different (Figure). Percutaneous coronary intervention was performed in 13.2% of FMD and 15.6% of non-FMD group, with similar success rates (75.8% vs. 69.2%, p=0.65). In-hospital and long-term MACE rate at median follow-up of 1032 (IQR 453–1096) days were not different between FMD and non-FMD groups (in-hospital: 5.6% vs. 8.3%, p=0.492; long-term: 19.6% vs. 15.6%, p=0.185).
Conclusion
In SCAD patients, severe coronary tortuosity was more prevalent in patients with FMD than those without. Despite the complex coronary anatomy, FMD was not associated with worse outcomes.
Differences in coronary manifestations
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Canadian Institutes of Health Research
Collapse
Affiliation(s)
- T Inohara
- Vancouver General Hospital, Vancouver, Canada
| | - M Alfadhel
- Vancouver General Hospital, Vancouver, Canada
| | - D Choi
- Vancouver General Hospital, Vancouver, Canada
| | | | - J Saw
- Vancouver General Hospital, Vancouver, Canada
| |
Collapse
|
15
|
Zhao JL, Zaidi S, Chan J, Wadosky K, Karthaus W, Choi D, Rivera AA, Gopalan A, Rathkopf D, Carver B, Abida W, Scher H, Chen Y, Goodrich D, Pe’er D, Sawyers CL. Abstract PO-134: Identification of the cells of origin and tumor heterogeneity in neuroendocrine prostate cancer (NEPC) by single-cell analysis. Cancer Res 2020. [DOI: 10.1158/1538-7445.tumhet2020-po-134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Lineage plasticity has emerged as an important mechanism of therapeutic resistance in prostate cancer treated with a newer generation of AR signaling inhibitor (ARSi). As a consequence of lineage plasticity, treatment resistant prostate cancer loses epithelial cell identity, acquires stem cell-like properties and transforms into a neuroendocrine lineage. Loss of function mutations in Tp53, Rb1 and Pten are enriched in human neuroendocrine prostate cancer (NEPC). To understand the cell of origin and the molecular mechanism underlying lineage plasticity and NEPC development, we have used single-cell RNA-sequencing (scRNA-seq) technology to profile a genetically engineered mouse model with probasin-Cre driven Tp53, Rb1 and Pten deletions (referred to as TKO mouse) and Rb1 and Pten deletions (referred to as DKO mouse). We have profiled ~70,000 single cells from 16 mice of various ages and 6 additional mice that have undergone castration with or without testosterone addback. Our scRNA-seq analysis captures a developmental trajectory from luminal adenocarcinoma to neuroendocrine tumor, suggesting a newly discovered luminal cell type (L2) within the normal prostate may be the preferred cell of origin for NEPC development. Furthermore, combining scRNA-seq, flow cytometry and immunofluorescence analysis, we reveal tremendous heterogeneity within the neuroendocrine tumors with differential expression of several putative drivers, including SOX2, EZH2, AURKA, NMYC and POU2F3. Many of these genes have been previously implicated as drivers of NEPC development, while POU2F3 has been identified as a defining marker for a Tuft-variant small cell lung cancer (SCLC). Lastly, we have preliminary evidence that castration may have the potential to accelerate the transition from adenocarcinoma to NEPC, while adding back testosterone may delay the process in the TKO mice. Overall, in this study, we have identified a luminal L2 population as the putative preferred cell of origin for NEPC in the TKO model and revealed a previous under-appreciated heterogeneity within NEPC with differential expression of driver transcriptional, epigenetic and cell cycle regulators, which mirrors what has been described in the SCLC field.
Citation Format: Jimmy L. Zhao, Samir Zaidi, Joseph Chan, Kristine Wadosky, Wouter Karthaus, Danielle Choi, Aura Agudelo Rivera, Anuradha Gopalan, Dana Rathkopf, Brett Carver, Wassim Abida, Howard Scher, Yu Chen, David Goodrich, Dana Pe’er, Charles L. Sawyers. Identification of the cells of origin and tumor heterogeneity in neuroendocrine prostate cancer (NEPC) by single-cell analysis [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-134.
Collapse
Affiliation(s)
- Jimmy L. Zhao
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | - Samir Zaidi
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | - Joseph Chan
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | | | | | - Danielle Choi
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | | | | | - Dana Rathkopf
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | - Brett Carver
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | - Wassim Abida
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | - Howard Scher
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | - Yu Chen
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | | | - Dana Pe’er
- 1Memorial Sloan Kettering Cancer Center, New York, NY,
| | | |
Collapse
|
16
|
Cha J, Son T, Ha J, Kim J, Hong S, Ahn C, Kim B, Ko Y, Choi D, Hong M, Jang Y. Machine learning for predicting fractional flow reserve based on optical coherence tomography in intermediate coronary stenosis. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Machine learning approaches using intravascular optical coherence tomography (OCT) to predict fractional flow reserve (FFR) have not been previously investigated. The objective of the study was to evaluate a machine learning method to estimate FFR based on intravascular OCT images in intermediate coronary lesions.
Methods
Data from both OCT- and wire-based FFR methods were obtained for lesions of the left anterior descending artery in 125 patients. Based on the total number of lesions, training and testing groups were partitioned at a ratio of 5:1. For the training group, 36 features, including 16 clinical and lesion characteristics, and 21 OCT features, were used to model machine learning-FFR. machine learning-FFR values were then derived for the testing group and compared with wire-based FFR values in terms of a diagnosis of ischemia (FFR <0.8).
Results
Clinical and lesion characteristics and OCT features between the training and testing groups were similar. During the machine learning modeling of the training group, six important features of machine learning-FFR were identified: minimal luminal area, percentage of the stenotic area, lesion length, proximal luminal area, pre-procedural platelet count, and hypertension. machine learning-FFR values showed a good correlation (r=0.853, P<0.001) with wire-based FFR values (Figure 1A). The diagnostic power of an FFR value less than 0.8, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of machine learning-FFR values for the testing group were 85.7%, 100%, 100%, 77.8%, and 90.5%, respectively (Figure 1B). Additionally, OCT-based machine learning-FFR values showed a good diagnostic accuracy compared with other image-based FFR values.
Conclusions
The OCT-based machine learning-FFR method can be used to simultaneously acquire information on both image and functional modalities using one invasive procedure, suggesting that it may be used to optimize treatments for intermediate coronary artery stenosis, as well as save time and cost.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Funded by the Korean government (MSIT) (no. 2017R1A2B2003191)
Collapse
Affiliation(s)
- J.J Cha
- Korea University Anam Hospital, Division of Cardiology, Department of Internal Medicine, Seoul, Korea (Republic of)
| | - T.D Son
- Yonsei University, Electrical Engineering, Seoul, Korea (Republic of)
| | - J Ha
- Yonsei University, Electrical Engineering, Seoul, Korea (Republic of)
| | - J.S Kim
- Yonsei University College of Medicine, Severance Cardiovascular Hospital, Department of Internal Medicine, Division of Cardiology, Seoul, Korea (Republic of)
| | - S.J Hong
- Yonsei University College of Medicine, Severance Cardiovascular Hospital, Department of Internal Medicine, Division of Cardiology, Seoul, Korea (Republic of)
| | - C.M Ahn
- Yonsei University College of Medicine, Severance Cardiovascular Hospital, Department of Internal Medicine, Division of Cardiology, Seoul, Korea (Republic of)
| | - B.K Kim
- Yonsei University College of Medicine, Severance Cardiovascular Hospital, Department of Internal Medicine, Division of Cardiology, Seoul, Korea (Republic of)
| | - Y.G Ko
- Yonsei University College of Medicine, Severance Cardiovascular Hospital, Department of Internal Medicine, Division of Cardiology, Seoul, Korea (Republic of)
| | - D Choi
- Yonsei University College of Medicine, Severance Cardiovascular Hospital, Department of Internal Medicine, Division of Cardiology, Seoul, Korea (Republic of)
| | - M.K Hong
- Yonsei University College of Medicine, Severance Cardiovascular Hospital, Department of Internal Medicine, Division of Cardiology, Seoul, Korea (Republic of)
| | - Y Jang
- Yonsei University College of Medicine, Severance Cardiovascular Hospital, Department of Internal Medicine, Division of Cardiology, Seoul, Korea (Republic of)
| |
Collapse
|
17
|
Choi D, Coda S, Decker J, Peysson Y. Modeling of the response function of CdTe detectors for a hard X-ray synthetic diagnostic. Fusion Engineering and Design 2020. [DOI: 10.1016/j.fusengdes.2020.111733] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
18
|
Liu S, Choi D, Romaniuk A, Graham J, Buller C, Cheema A. NATURAL HISTORY OF SPONTANEOUS CORONARY ARTERY DISSECTIONS (SCAD): FINDINGS OF A ROUTINE SURVEILLANCE ANGIOGRAPHIC STUDY. Can J Cardiol 2020. [DOI: 10.1016/j.cjca.2020.07.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
19
|
Karthaus W, Hofree M, Choi D, Linton EL, Turkekul M, Bejnood A, Carver B, Gopalan A, Laudone V, Biton M, Chaudhary O, Masilionis I, Mazutis L, Pe'er D, Regev A, Sawyers C. Abstract 5722: Acquired stemness by luminal cells. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Rare cell types in the prostate are reported to have stem cell properties based on organ regeneration potential following castration. Here, we use single cell RNA-seq (scRNA-Seq) to characterize these populations from the murine and human prostate in hormonally intact and androgen deprived conditions. Prostate cells from hormonally intact mice partitioned into one large subset of basal epithelial cells, another large subset of luminal epithelial cells, which we designate luminal 1 and two rare luminal populations: luminal 2 and luminal 3. Luminal cells that persist following castration display enhanced organoid regeneration potential, particularly within 1-2 days of androgen addback, and contribute equipotently to prostatic regeneration as revealed by lineage tracing. This regeneration is mediated, in part, through the orchestrated expression of Nrg2, Igf1, Fgf10 and Rspo3 by distinct populations of androgen-responsive mesenchymal and smooth muscle cells. Thus, luminal cells that persist post-castration undergo a cell state change that primes a proliferative response to microenvironment signals, analogous to other models of tissue injury such as liver damage.
Citation Format: Wouter Karthaus, Matan Hofree, Danielle Choi, Eliot L. Linton, Mesruh Turkekul, Alborz Bejnood, Brett Carver, Anuhandra Gopalan, Vincent Laudone, Moshe Biton, Ojasvi Chaudhary, Ignas Masilionis, Linas Mazutis, Dana Pe'er, Aviv Regev, Charles Sawyers. Acquired stemness by luminal cells [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5722.
Collapse
|
20
|
Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell 2020; 38:279-296.e9. [PMID: 32679108 PMCID: PMC7472556 DOI: 10.1016/j.ccell.2020.06.005] [Citation(s) in RCA: 124] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2020] [Revised: 04/27/2020] [Accepted: 06/05/2020] [Indexed: 01/03/2023]
Abstract
Despite the development of second-generation antiandrogens, acquired resistance to hormone therapy remains a major challenge in treating advanced prostate cancer. We find that cancer-associated fibroblasts (CAFs) can promote antiandrogen resistance in mouse models and in prostate organoid cultures. We identify neuregulin 1 (NRG1) in CAF supernatant, which promotes resistance in tumor cells through activation of HER3. Pharmacological blockade of the NRG1/HER3 axis using clinical-grade blocking antibodies re-sensitizes tumors to hormone deprivation in vitro and in vivo. Furthermore, patients with castration-resistant prostate cancer with increased tumor NRG1 activity have an inferior response to second-generation antiandrogen therapy. This work reveals a paracrine mechanism of antiandrogen resistance in prostate cancer amenable to clinical testing using available targeted therapies.
Collapse
Affiliation(s)
- Zeda Zhang
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Wouter R Karthaus
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Young Sun Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Vianne R Gao
- Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Chao Wu
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Joshua W Russo
- Hematology-Oncology Division, Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Menghan Liu
- Sackler Institute of Graduate Biomedical Sciences, New York University School of Medicine, New York, NY 10016, USA
| | - Jose Mauricio Mota
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Wassim Abida
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Eliot Linton
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Eugine Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Spencer D Barnes
- Bioinformatics Core Facility of the Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Hsuan-An Chen
- Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Ninghui Mao
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - John Wongvipat
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Danielle Choi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Xiaoping Chen
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Huiyong Zhao
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Katia Manova-Todorova
- Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Elisa de Stanchina
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Mary-Ellen Taplin
- Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Steven P Balk
- Hematology-Oncology Division, Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Dana E Rathkopf
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Anuradha Gopalan
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Brett S Carver
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
| | - Ping Mu
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Xuejun Jiang
- Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA.
| | - Philip A Watson
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA.
| | - Charles L Sawyers
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20185, USA.
| |
Collapse
|
21
|
Ha M, Son YR, Kim J, Park SM, Hong CM, Choi D, Kang W, Kim JH, Lee KJ, Park D, Han ME, Oh SO, Lee D, Kim YH. TEK is a novel prognostic marker for clear cell renal cell carcinoma. Eur Rev Med Pharmacol Sci 2020; 23:1451-1458. [PMID: 30840266 DOI: 10.26355/eurrev_201902_17102] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. However, effective therapeutics for ccRCC are lacking. Novel biomarkers could provide critical information when determining prognoses for patients with ccRCC. In this study, we sought to determine if the expression of receptor tyrosine kinase (TEK) could be a potential novel prognostic biomarker for ccRCC. TEK, originally identified as an endothelial cell-specific receptor, plays an important role in the modulation of vasculogenesis and remodeling. Altered TEK expression has been observed in tumor tissues (e.g., oral squamous cell carcinomas, leukemia) and breast, gastric and thyroid cancers. However, the role of TEK in ccRCC remains unknown. PATIENTS AND METHODS Differential TEK expression between non-metastatic (stage M0) and metastatic (stage M1) ccRCC patient cohorts was determined from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). Furthermore, TEK expression was assessed as a prognostic factor using the time-dependent area under the curve (AUC) of Uno's C-index, the AUC value of the receiver operating characteristics (ROC) at 5 years, Kaplan-Meier survival curves and multivariate analyses. RESULTS A Kaplan-Meier curve analysis revealed that the downregulation of TEK expression was associated with a poor prognosis for patients with ccRCC with good discrimination (p<0.0001 and p=0.0044 for the TGCA and ICGC cohorts, respectively). Analyses of C-indices and receiver operating characteristic AUC values further support this discriminative ability. Moreover, multivariate analyses showed the prognostic significance of TEK expression levels (p<0.001). CONCLUSIONS Although additional clinical investigations will be needed, our results suggest that TEK is a potential biomarker for ccRCC.
Collapse
Affiliation(s)
- M Ha
- Department of Anatomy, Pusan National University School of Medicine, Yangsan, Republic of Korea.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Cheng X, Redanz S, Treerat P, Qin H, Choi D, Zhou X, Xu X, Merritt J, Kreth J. Magnesium-Dependent Promotion of H 2O 2 Production Increases Ecological Competitiveness of Oral Commensal Streptococci. J Dent Res 2020; 99:847-854. [PMID: 32197054 PMCID: PMC7313347 DOI: 10.1177/0022034520912181] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The pyruvate oxidase (SpxB)-dependent production of H2O2 is widely distributed among oral commensal streptococci. Several studies confirmed the ability of H2O2 to antagonize susceptible oral bacterial species, including caries-associated Streptococcus mutans as well as several periodontal pathobionts. Here we report a potential mechanism to bolster oral commensal streptococcal H2O2 production by magnesium (Mg2+) supplementation. Magnesium is a cofactor for SpxB catalytic activity, and supplementation increases the production of H2O2 in vitro. We demonstrate that Mg2+ affects spxB transcription and SpxB abundance in Streptococcus sanguinis and Streptococcus gordonii. The competitiveness of low-passage commensal streptococcal clinical isolates is positively influenced in antagonism assays against S. mutans. In growth conditions normally selective for S. mutans, Mg2+ supplementation is able to increase the abundance of S. sanguinis in dual-species biofilms. Using an in vivo biophotonic imaging platform, we further demonstrate that dietary Mg2+ supplementation significantly improves S. gordonii oral colonization in mice. In summary, our results support a role for Mg2+ supplementation as a potential prebiotic to promote establishment of oral health-associated commensal streptococci.
Collapse
Affiliation(s)
- X. Cheng
- The State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China,Department of Geriatric Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - S. Redanz
- Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA
| | - P. Treerat
- Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA
| | - H. Qin
- Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA
| | - D. Choi
- Department of Community Dentistry, School of Dentistry, Oregon Health & Science University, Portland, OR, USA,School of Public Health, Oregon Health & Science University, Portland, OR, USA
| | - X. Zhou
- The State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China,Department of Cariology and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - X. Xu
- The State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China,Department of Cariology and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - J. Merritt
- Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA,Department of Restorative Dentistry, Oregon Health and Science University, Portland, OR, USA
| | - J. Kreth
- Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA,Department of Restorative Dentistry, Oregon Health and Science University, Portland, OR, USA,J. Kreth, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd., MRB433, Portland, OR 97239, USA.
| |
Collapse
|
23
|
Bhushan A, Choi D, Maresh G, Deodhar A. SAT0247 PREDICTORS OF ADVERSE OUTCOMES IN DIFFUSE ALVEOLAR HEMORRHAGE OF IMMUNE AND NON-IMMUNE CAUSES: 12-YEAR EXPERIENCE FROM A UNIVERSITY HOSPITAL. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Diffuse alveolar hemorrhage (DAH) is a rare, life-threatening condition that has either immune or non-immune etiologies1. DAH caused by capillaritis can be immune-mediated (IM-DAH), e.g. anti-neutrophil cytoplasmic antibody (ANCA) vasculitis and systemic lupus erythematosus, but DAH may also result from anticoagulation, heart failure, drugs or inhaled toxins. Since IM-DAH has specific therapies available, we hypothesized that patients with IM-DAH would have a better prognosis.Objectives:We did a retrospective analysis of all DAH cases seen at our university hospital in the last 12 years to investigate the predictors of adverse outcomes.Methods:Using Epic radiant and Agfa Radiology Information System databases, we queried electronic medical records of all patients admitted to our university between Jan 2007 to Jan 2019 who had the words “diffuse alveolar hemorrhage” in their chest x-ray report. We manually reviewed charts of all these patients to confirm true DAH. True DAH was defined as suspicion of DAH on chest x-ray plus inclusion of DAH on the discharge problem list. We did a detailed chart review of true DAH cases to extract information regarding demographics, baseline disease characteristics, physical/serology/imaging findings, treatment received, and outcomes. The outcomes of interest were death, intubation, shock, need for hemodialysis (HD), and red blood cell transfusions. We compared IM-DAH with non IM-DAH cases using descriptive statistics, t-test, and chi-squared tests. We used logistic regression models to assess the influence of baseline characteristics on outcomes. A p-value < 0.05 was considered statistically significant.Results:There were 88 cases of DAH (M:F 54:34, median age 57) fulfilling inclusion criteria (Table 1). The non-immune etiology was diagnosed in 63%, while 36% were IM-DAH (18% ANCA associated, 9% SLE, 2% decompensated heart failure, the rest were others). No clear etiology for DAH was found in 37.5% cases. Death within 90 days of onset of DAH occurred in 37.5%, 5.6% had recurrent DAH, and 56.8% had sustained remission. Non-IM DAH cases had worse outcomes such as death and were less likely to experience sustained remission (Chi-squared = 19.1, p < 0.001), though IM-DAH were more likely to receive HD (Chi-squared = 7.5, p-value 0.01). Presence of extrapulmonary findings (e.g. nephritis) was a risk factor for adverse outcome, and was statistically significantly correlated with the amount of blood products received, need for HD and likelihood of death, which did not reach statistical significance. Shock and intubation were associated with a higher likelihood of death (p = 0.02 and p = 0.001, respectively).Table 1.Comparison of Clinical Characteristics of Immune versus Non-Immune Cases of Diffuse Alveolar HemorrhageVariableImmune cases(N = 32)Non-immune cases(N = 56)Statistical comparisonAge (years)51.0955.91P = 0.196%Female43.835.7P = 0.510%presenting with hemoptysis8 (25%)14 (25%)P = 0.101%extrapulmonary findings20 (62.5%)1 (1.7%)P = 6.9*e-10pANCA positive16 (50%)2 (3.6%)P = 0.0004% on anticoagulation9.42.5P = 0.090Mean Creatinine2.381.89P = 0.507Mean hospital length of stay (days)16.6923.27P = 0.139Drop in Hemoglobin prior to DAH and day of DAH0.241.17P = 0.070%Bronchoscopy-confirmed DAH62.575.0P = 0694Mean units of blood transfused1.912.66P = 0.448%Need for hemodialysis37.512.5P = 0.010%Shock (any kind)21.932.1P = 0.338%Need for intubation43.862.5P = 0.122%Death within 90 days12.552.7P = 0.0009Conclusion:DAH, a life-threatening condition, has both immune and non-immune etiologies. Our 12-years, single-center, university hospital experience showed that IM-DAH has a better prognosis than non IM-DAH. Presence of extrapulmonary manifestations was associated with worse outcomes.References:[1]Moo Suk Park. Diffuse Alveolar Hemorrhage. Tuberc Respir Dis (Seoul). 2013 Apr; 74(4): 151–162.[2]Nasser M, Cottin V. Alveolar Hemorrhage in Vasculitis (Primary and Secondary). Semin Respir Crit Care Med. 2018 Aug;39(4):482-493.Disclosure of Interests:Ambika Bhushan: None declared, Dongseok Choi: None declared, Guy Maresh: None declared, Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB
Collapse
|
24
|
Karthaus WR, Hofree M, Choi D, Linton EL, Turkekul M, Bejnood A, Carver B, Gopalan A, Abida W, Laudone V, Biton M, Chaudhary O, Xu T, Masilionis I, Manova K, Mazutis L, Pe'er D, Regev A, Sawyers CL. Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science 2020; 368:497-505. [PMID: 32355025 DOI: 10.1126/science.aay0267] [Citation(s) in RCA: 127] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 03/14/2020] [Indexed: 01/20/2023]
Abstract
Androgen deprivation is the cornerstone of prostate cancer treatment. It results in involution of the normal gland to ~90% of its original size because of the loss of luminal cells. The prostate regenerates when androgen is restored, a process postulated to involve stem cells. Using single-cell RNA sequencing, we identified a rare luminal population in the mouse prostate that expresses stemlike genes (Sca1 + and Psca +) and a large population of differentiated cells (Nkx3.1 +, Pbsn +). In organoids and in mice, both populations contribute equally to prostate regeneration, partly through androgen-driven expression of growth factors (Nrg2, Rspo3) by mesenchymal cells acting in a paracrine fashion on luminal cells. Analysis of human prostate tissue revealed similar differentiated and stemlike luminal subpopulations that likewise acquire enhanced regenerative potential after androgen ablation. We propose that prostate regeneration is driven by nearly all persisting luminal cells, not just by rare stem cells.
Collapse
Affiliation(s)
- Wouter R Karthaus
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Matan Hofree
- Klarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Danielle Choi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Eliot L Linton
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Mesruh Turkekul
- Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Alborz Bejnood
- Klarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Brett Carver
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Anuradha Gopalan
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Wassim Abida
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Vincent Laudone
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Moshe Biton
- Klarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
| | - Ojasvi Chaudhary
- Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Tianhao Xu
- Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Ignas Masilionis
- Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Katia Manova
- Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Linas Mazutis
- Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Dana Pe'er
- Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.,Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Aviv Regev
- Klarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA. .,Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.,Koch Institute of Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Charles L Sawyers
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. .,Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
| |
Collapse
|
25
|
Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell 2020; 37:584-598.e11. [PMID: 32220301 PMCID: PMC7292228 DOI: 10.1016/j.ccell.2020.03.001] [Citation(s) in RCA: 79] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 11/04/2019] [Accepted: 02/28/2020] [Indexed: 12/25/2022]
Abstract
Metastatic prostate cancer is characterized by recurrent genomic copy number alterations that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss as a cause of antiandrogen resistance in an in vivo small hairpin RNA (shRNA) screen of 730 genes deleted in prostate cancer. ATAC-seq and RNA-seq analyses showed that CHD1 loss resulted in global changes in open and closed chromatin with associated transcriptomic changes. Integrative analysis of this data, together with CRISPR-based functional screening, identified four transcription factors (NR3C1, POU3F2, NR2F1, and TBX2) that contribute to antiandrogen resistance, with associated activation of non-luminal lineage programs. Thus, CHD1 loss results in chromatin dysregulation, thereby establishing a state of transcriptional plasticity that enables the emergence of antiandrogen resistance through heterogeneous mechanisms.
Collapse
MESH Headings
- Androgen Antagonists/pharmacology
- Animals
- Apoptosis
- Biomarkers, Tumor/genetics
- Cell Proliferation
- Chromatin/genetics
- Chromatin/metabolism
- DNA Helicases/antagonists & inhibitors
- DNA Helicases/genetics
- DNA-Binding Proteins/antagonists & inhibitors
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/metabolism
- Drug Resistance, Neoplasm/genetics
- Gene Expression Regulation, Neoplastic
- High-Throughput Screening Assays
- Humans
- Male
- Mice
- Prostatic Neoplasms, Castration-Resistant/drug therapy
- Prostatic Neoplasms, Castration-Resistant/genetics
- Prostatic Neoplasms, Castration-Resistant/pathology
- RNA, Small Interfering/genetics
- Receptors, Androgen/chemistry
- Receptors, Androgen/genetics
- Transcription Factors/metabolism
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Zeda Zhang
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Chuanli Zhou
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Xiaoling Li
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Spencer D Barnes
- Bioinformatics Core Facility of the Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Su Deng
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Elizabeth Hoover
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Chi-Chao Chen
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA
| | - Young Sun Lee
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Yanxiao Zhang
- Ludwig Institute for Cancer Research, La Jolla, CA, USA
| | - Choushi Wang
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Lauren A Metang
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Chao Wu
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | | | - Nickolas A Johnson
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - John Wongvipat
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | | | - Zhen Cao
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA
| | - Danielle Choi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Chun-Hao Huang
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA
| | - Eliot Linton
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Xiaoping Chen
- Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Yupu Liang
- Center for Clinical and Translational Science, Rockefeller University, New York, NY 10065, USA
| | - Christopher E Mason
- Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA; The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA; The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, USA
| | - Elisa de Stanchina
- Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Wassim Abida
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Amaia Lujambio
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Sheng Li
- The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA
| | - Scott W Lowe
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
| | - Joshua T Mendell
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
| | - Venkat S Malladi
- Bioinformatics Core Facility of the Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA
| | - Charles L Sawyers
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
| | - Ping Mu
- Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Hamon Center for Regenerative Science and Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
| |
Collapse
|
26
|
Abstract
UNLABELLED Few studies have explored the association of oral bisphosphonate exposure and gastrointestinal cancer within Asian populations. In this study, we investigated 45,397 Korean women from the nationwide population-based cohort from 2002 to 2013. Oral bisphosphonate exposure did not appear to be associated with elevated or reduced risk for gastrointestinal cancer. INTRODUCTION While several studies suggested increased risk in upper gastrointestinal (GI) cancer or reduced risk in colorectal cancer upon bisphosphonate exposure, the association is less explored within Asian populations. We investigated the effect of oral bisphosphonate exposure on the risk of GI cancers within a nationwide population-based cohort. METHODS This study used two separate cohorts. The first cohort included 45,397 women aged 60 years or older from the National Health Insurance Service-Health Screening Cohort during 2002-2013. Participants were classified into bisphosphonate users and non-users based on drug exposure during 2002-2007, and followed-up from the index date of January 1, 2008. The second cohort included 25,665 newly diagnosed osteoporosis patients who started taking oral bisphosphonate during 2003-2008. After 4 years of drug exposure period, patients were separated into quartiles based on cumulative oral bisphosphonate exposure. Participants were followed-up until December 31, 2013 for GI cancer, stomach cancer, and colorectal cancer. Cox proportional hazard regression models were used to assess the hazard ratios (HRs) and 95% confidence intervals (CIs) for the cancer risks. RESULTS Compared to bisphosphonate non-users, no significant risk difference was observed among bisphosphonate users on GI (HR 1.06; 95% CI 0.87-1.28), stomach (HR 1.11; 95% CI 0.85-1.47) and colorectal cancers (HR 1.04; 95% CI 0.79-1.37). Among bisphosphonate users, increasing doses of bisphosphonate exposure was not associated with elevated or reduced risk for GI cancer (p for trend 0.573). CONCLUSION Oral bisphosphonate use did not appear to be associated with elevated or reduced risk for GI cancers.
Collapse
Affiliation(s)
- D Choi
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea
- Pyeongchang Health Center and County Hospital, Pyeongchang, South Korea
| | - S Choi
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea
| | - J Chang
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea
| | - S M Park
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea.
- Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea.
| |
Collapse
|
27
|
Mao N, Gao D, Hu W, Gadal S, Hieronymus H, Wang S, Lee YS, Sullivan P, Zhang Z, Choi D, Rosen N, Sawyers CL, Gopalan A, Chen Y, Carver BS. Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2. Cancer Res 2020; 80:1428-1437. [PMID: 32015092 DOI: 10.1158/0008-5472.can-19-1394] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2019] [Revised: 10/25/2019] [Accepted: 01/29/2020] [Indexed: 11/16/2022]
Abstract
Genomic rearrangements leading to the aberrant expression of ERG are the most common early events in prostate cancer and are significantly enriched for the concomitant loss of PTEN. Genetically engineered mouse models reveal that ERG overexpression alone is not sufficient to induce tumorigenesis, but combined loss of PTEN results in an aggressive invasive phenotype. Here, we show that oncogenic ERG repressed PI3K signaling through direct transcriptional suppression of IRS2, leading to reduced RTK levels and activity. In accordance with this finding, ERG-positive human prostate cancers had a repressed AKT gene signature and transcriptional downregulation of IRS2. Although overexpression of IRS2 activated PI3K signaling, promoting cell migration in a PI3K-dependent manner, this did not fully recapitulate the phenotype seen with loss of PTEN as PI3K signaling is not as robust as observed in the setting of loss of PTEN. Importantly, deletions of the PTEN locus, which promotes active PI3K signaling, were among the most significant copy-number alterations that co-occurred with ERG genomic rearrangements. This work provides insight on how initiating oncogenic events may directly influence the selection of secondary concomitant alterations to promote oncogenic signaling during tumor evolution. SIGNIFICANCE: This work provides insight on how initiating oncogenic events may directly influence the selection of secondary concomitant alterations to promote tumorigenesis.
Collapse
Affiliation(s)
- Ninghui Mao
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Dong Gao
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Wenhuo Hu
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sunyana Gadal
- Molecular Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Haley Hieronymus
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Shangqian Wang
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Young Sun Lee
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Patrick Sullivan
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Zeda Zhang
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Danielle Choi
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Neal Rosen
- Molecular Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York.,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Charles L Sawyers
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Anuradha Gopalan
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Yu Chen
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Brett S Carver
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. .,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.,Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
28
|
Carr AS, Shah S, Choi D, Blake J, Phadke R, Gilbertson J, Whelan CJ, Wechalekar AD, Gillmore JD, Hawkins PN, Reilly MM. Spinal Stenosis in Familial Transthyretin Amyloidosis. J Neuromuscul Dis 2019; 6:267-270. [PMID: 30856118 DOI: 10.3233/jnd-180348] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Here we describe a patient with genetically confirmed ATTR, a family history of the disease and histological confirmation following carpal tunnel release surgery but no other manifestations. The first major neurological or systemic manifestation was cauda equina syndrome with ATTR deposits contributing to lumbar spinal stenosis. Recent gene therapy trials showed improvement in the neuropathy in TTR amyloidosis. This case highlights the need for awareness of the heterogeneous neurological phenotype seen in ATTR to aid earlier diagnosis especially now that disease modifying therapies are available.
Collapse
Affiliation(s)
- A S Carr
- Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
| | - S Shah
- Department of Neuroradiology, National Hospital of Neurology and Neurosurgery, Queen Square, London, UK
| | - D Choi
- Department of Neurosurgery, National Hospital of Neurology and Neurosurgery, Queen Square, London, UK
| | - J Blake
- Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.,Department of Clinical Neurophysiology, Norfolk and Norwich University Hospital, Norwich UK
| | - R Phadke
- Department of Neuropathology, National Hospital of Neurology and Neurosurgery, Queen Square, London, UK
| | - J Gilbertson
- National Amyloidosis Centre, Royal Free Hospital, Rowland Hill Street, London, UK
| | - C J Whelan
- National Amyloidosis Centre, Royal Free Hospital, Rowland Hill Street, London, UK
| | - A D Wechalekar
- National Amyloidosis Centre, Royal Free Hospital, Rowland Hill Street, London, UK
| | - J D Gillmore
- National Amyloidosis Centre, Royal Free Hospital, Rowland Hill Street, London, UK
| | - P N Hawkins
- National Amyloidosis Centre, Royal Free Hospital, Rowland Hill Street, London, UK
| | - M M Reilly
- Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
| |
Collapse
|
29
|
Pappas KJ, Choi D, Sawyers CL, Karthaus WR. Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses. J Vis Exp 2019. [PMID: 31710046 DOI: 10.3791/60346] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Presented here is a protocol to study pharmacodynamics, stem cell potential, and cancer differentiation in prostate epithelial organoids. Prostate organoids are androgen responsive, three-dimensional (3D) cultures grown in a defined medium that resembles the prostatic epithelium. Prostate organoids can be established from wild-type and genetically engineered mouse models, benign human tissue, and advanced prostate cancer. Importantly, patient derived organoids closely resemble tumors in genetics and in vivo tumor biology. Moreover, organoids can be genetically manipulated using CRISPR/Cas9 and shRNA systems. These controlled genetics make the organoid culture attractive as a platform for rapidly testing the effects of genotypes and mutational profiles on pharmacological responses. However, experimental protocols must be specifically adapted to the 3D nature of organoid cultures to obtain reproducible results. Described here are detailed protocols for performing seeding assays to determine organoid formation capacity. Subsequently, this report shows how to perform drug treatments and analyze pharmacological response via viability measurements, protein isolation, and RNA isolation. Finally, the protocol describes how to prepare organoids for xenografting and subsequent in vivo growth assays using subcutaneous grafting. These protocols yield highly reproducible data and are widely applicable to 3D culture systems.
Collapse
Affiliation(s)
- Kyrie J Pappas
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
| | - Danielle Choi
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
| | - Charles L Sawyers
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute
| | - Wouter R Karthaus
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center;
| |
Collapse
|
30
|
Kim YH, Her AY, Jeong MH, Kim BK, Lee SY, Hong SJ, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. P4393Current smoking and gender difference in South Korean AMI patients who underwent PCI with DES. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
There is some debate on whether or not there is a gender difference is present between current smoking and cardiovascular disease.
Purpose
We decide to evaluate the impact of sex difference on the 2-year clinical outcomes in Korean acute myocardial infarction (AMI) patients who currently smoke and who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
Methods
The data of this study was obtained from the Korea Acute Myocardial Infarction (KAMIR) registry. More than fifty high-volume universites or community hospitals with facilities for primary PCI and onsite cardiac surgery participated in this KAMIR registry. A total of 12565 current smoker AMI patients were enrolled and divided into the male (n=11767, 93.6%) or female (n=798, 6.4%) group. The clinical endpoint was the occurrence of major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), and total repeat revascularization.
Results
Before risk adjustment, the cumulative incidences of MACE (7.2% vs. 10.0%, hazard ratio [HR], 1.419; 95% confidence interval [CI], 1.125–1.790; P=0.003), all-cause death (HR, 1.988; 95% CI, 1.417–2.789; P<0.001), and re-MI (HR, 1.885; 95% CI, 1.154–3.078; P=0.011) were significantly higher in the female group compared with the male group. However, after adjustment the cumulative incidences of MACE (adjusted HR, 1.047; 95% CI, 0.756–1.450; P=0.782), all-cause death, re-MI, total repeat revascularization, TLR, TVR, and non-TVR were similar between the two groups.
Clinical outcomes at 2-year Outcomes Cumulative Events at 2-year (%) Unadjusted Adjusted* Propensity-score adjusted Male Female Log-rank Hazard Ratio (95% CI) p value Hazard Ratio (95% CI) p value Hazard Ratio (95% CI) p value MACE 819 (7.2) 78 (10.0) 0.003 1.419 (1.125–1.790) 0.003 1.047 (0.756–1.450) 0.782 1.133 (0.871–1.473) 0.352 All-cause death 283 (2.5) 38 (4.8) <0.001 1.988 (1.417–2.789) <0.001 0.764 (0.457–1.279) 0.306 1.105 (0.744–1.641) 0.620 Cardiac death 224 (1.9) 25 (3.2) 0.016 1.654 (1.094–2.500) 0.017 0.512 (0.261–1.005) 0.052 0.822 (0.511–1.322) 0.419 Re-MI 142 (1.3) 18 (2.4) 0.010 1.885 (1.154–3.078) 0.011 1.741 (0.887–3.419) 0.107 1.835 (1.109–3.375) 0.062 Total revascularization 444 (4.0) 27 (3.6) 0.594 0.900 (0.610–1.327) 0.594 1.069 (0.654–1.748) 0.789 0.956 (0.627–1.458) 0.835 TLR 121 (1.1) 8 (1.1) 0.956 0.980 (0.479–2.004) 0.956 0.955 (0.366–2.497) 0.926 0.868 (0.395–1.910) 0.726 TVR 228 (2.1) 14 (1.9) 0.726 0.908 (0.529–1.558) 0.726 1.051 (0.518–2.135) 0.890 0.935 (0.519–1.684) 0.823 Non-TVR 223 (2.0) 13 (1.7) 0.602 0.862 (0.493–1.508) 0.602 1.060 (0.536–2.097) 0.867 0.942 (0.514–1.726) 0.847
Conclusion
Before risk adjustment, a gender difference was suggested in the female group compared with the male in these current smoker South Korean AMI patients during a 2-year follow-up period. However, after adjustment, gender difference was not observed in these AMI patients with a history of current smoking.
Collapse
Affiliation(s)
- Y H Kim
- Kangwon National University School of Medicine, Chuncheon City, Korea (Republic of)
| | - A.-Y Her
- Kangwon National University School of Medicine, Chuncheon City, Korea (Republic of)
| | - M H Jeong
- Chonnam National University Hospital, Department of Cardiology, Gwangju, Korea (Republic of)
| | - B.-K Kim
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - S.-Y Lee
- Sanbon Hospital, Wonkwang University College of Medicine, Department of Cardiology, Gunpo, Korea (Republic of)
| | - S.-J Hong
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - D.-H Shin
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - C.-M Ahn
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - J.-S Kim
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - Y.-G Ko
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - D Choi
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - M.-K Hong
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - Y Jang
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| |
Collapse
|
31
|
Kim YH, Her AY, Jeong MH, Kim BK, Lee SY, Hong SJ, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. P833Two-year clinical outcomes between statin with ACE inhibitor or ARB in patients with ST-segment elevation myocardial infarction after successful PCI with DES. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Limited comparative data are available.
Purpose
We decided to compare 2-year major clinical outcomes between statin with ACEI and statin ARB therapy in patients with STEMI after PCI with drug-eluting stents (DES).
Methods
A total 11706 STEMI patients who underwent PCI with DES and who prescribed statin were enrolled and they were divided into two groups, the statin with ACEI group (n=8705) and the statin with ARB group (n=3001). The primary endpoint was the major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-TVR. The secondary endpoints were the cumulative incidences of individual components of MACE and target vessel failure (TVF), a composite of death related to the target vessel, re-MI, or clinically driven TVR.
Results
Two PSM groups (2835 pairs, n=5670, C-statistic = 0.680) were generated. The relative risk of MACE was higher in the statin with ARB group compared to statin with ACEI groups after propensity score-matched (PSM) analysis (hazard ratio [HR]: 1.323, 95% confidence interval [CI]: 1.085–1.613, p=0.006). The relative risks of cardiac death (HR: 1.831, 95% CI: 1.199–2.740, p=0.005), total repeat revascularization (HR: 1.487, 95% CI: 1.133–1.950, p=0.004), and non-TVR (HR: 1.696, 95% CI: 1.122–2.564, p=0.012) were also higher in the statin with ARB group after PSM.
Outcomes Cumulative Events at 2-year (%) Hazard Ratio (95% CI) p value Statin + ACEI Statin + ARB Log-rank Propensity score matched Patients MACE 173 (6.5) 225 (8.5) 0.006 1.323 (1.085–1.613) 0.006 All-cause death 58 (2.2) 80 (3.0) 0.054 1.391 (0.992–1.950) 0.056 Cardiac death 35 (1.3) 63 (2.3) 0.004 1.831 (1.199–2.740) 0.005 Re-MI 39 (1.5) 44 (1.7) 0.548 1.141 (0.742–1.756) 0.548 Total repeat revascularization 88 (3.4) 128 (4.9) 0.004 1.487 (1.133–1.950) 0.004 TLR 26 (1.0) 40 (1.5) 0.075 1.561 (0.953–2.558) 0.077 TVR 53 (2.0) 71 (2.8) 0.086 1.364 (0.955–1.946) 0.088 Non-TVR 36 (1.4) 60 (2.3) 0.011 1.696 (1.122–2.564) 0.012 TVF 140 (5.3) 173 (6.6) 0.050 1.249 (1.000–1.561) 0.050
Conclusions
In this study, we suggest that the combination of statin with ACEI may be beneficial for reducing the cumulative incidences of MACE, total repeat revascularization rate, and non-TVR rather than the statin with ARB after PCI with DES in STEMI patients.
Collapse
Affiliation(s)
- Y H Kim
- Kangwon National University School of Medicine, Chuncheon City, Korea (Republic of)
| | - A.-Y Her
- Kangwon National University School of Medicine, Chuncheon City, Korea (Republic of)
| | - M.-H Jeong
- Chonnam National University Hospital, Department of Cardiology, Gwangju, Korea (Republic of)
| | - B.-K Kim
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - S.-Y Lee
- Sanbon Hospital, Wonkwang University College of Medicine, Department of Cardiology, Gunpo, Korea (Republic of)
| | - S.-J Hong
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - D.-H Shin
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - C.-M Ahn
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - J.-S Kim
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - Y.-G Ko
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - D Choi
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - M.-K Hong
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - Y Jang
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| |
Collapse
|
32
|
Kim YH, Her AY, Jeong MH, Kim BK, Lee SY, Hong SJ, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. P5362Impact of statin therapy on long-term clinical outcomes between STEMI and NSTEMI after stent implantation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Although European guideline recommends that statin should be given to all patients with acute myocardial infarction (AMI), irrespective of cholesterol concentration, limited studies were focused on the long-term effects of statin therapy between ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI).
Purpose
The authors conducted the study to compare the relative beneficial role of statin on 2-year major clinical outcomes between STEMI and NSTEMI in patients who underwent successful PCI with DES.
Methods
Finally, a total of 26317 AMI patients who underwent stent implantation and who were prescribed the statin were enrolled and they were separated into two groups; the STEMI group (n=15002) and the NSTEMI group (n=11315). The clinical endpoint was the occurrence of major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), total coronary revascularization (target lesion revascularization [TLR], target vessel revascularization [TVR], non-TVR) during 2-year follow-up period.
Results
After propensity score-matched (PSM) analysis, two PSM groups (7746 pairs, n=15492, C-statistic = 0.766) were generated. In the total study population, the cumulative incidences of MACE, all-cause death, and cardiac death were significantly higher in the NSTEMI group. However, after PSM, the cumulative incidence of all-cause death (Hazard ratio, 1.386; 95% CI, 1.133–1.696; p=0.002) was significantly higher in the NSTEMI group. The cumulative incidences of MACE, cardiac death, re-MI, total revascularization, TLR, TVR, and non-TVR were similar between the two groups (Table 1).
Outcomes Cumulative Events at 2-year (%) Hazard Ratio (95% CI) p value STEMI NSTEMI Log-rank Propensity score matched patients MACE 532 (7.2) 584 (8.1) 0.092 1.106 (0.984–1.244) 0.092 All-cause death 163 (2.2) 224 (3.1) 0.001 1.386 (1.133–1.696) 0.002 Cardiac death 121 (1.5) 148 (2.0) 0.088 1.232 (0.969–1.566) 0.089 Re-MI 117 (1.6) 107 (1.5) 0.545 0.922 (0.710–1.199) 0.545 Total revascularization 291 (4.1) 307 (4.4) 0.422 1.068 (0.910–1.254) 0.423 TLR 92 (1.3) 89 (1.2) 0.880 0.978 (0.731–1.309) 0.880 TVR 173 (2.4) 184 (2.6) 0.478 1.078 (0.876–1.327) 0.478 Non-TVR 123 (1.7) 130 (1.9) 0.593 1.070 (0.836–1.369) 0.539
Conclusion
The mortality reduction capability of statin was more prominent in the STEMI group compared with the NSTEMI group.
Collapse
Affiliation(s)
- Y H Kim
- Kangwon National University School of Medicine, Chuncheon City, Korea (Republic of)
| | - A.-Y Her
- Kangwon National University School of Medicine, Chuncheon City, Korea (Republic of)
| | - M H Jeong
- Chonnam National University Hospital, Department of Cardiology, Gwangju, Korea (Republic of)
| | - B.-K Kim
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - S.-Y Lee
- Sanbon Hospital, Wonkwang University College of Medicine, Department of Cardiology, Gunpo, Korea (Republic of)
| | - S.-J Hong
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - D.-H Shin
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - C.-M Ahn
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - J.-S Kim
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - Y.-G Ko
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - D Choi
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - M.-K Hong
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - Y Jang
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| |
Collapse
|
33
|
Kim YH, Her AY, Jeong MH, Kim BK, Lee SY, Hong SJ, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. P5494Impact of the gender difference on long-term clinical outcomes in dyslipidemic South Korean AMI patients who underwent PCI with new-generation DES. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
There are limited comparative data concerning long-term major clinical outcomes between male and female in dyslipidemic AMI patients after PCI with new-generation DES.
Purpose
We thought to investigate the impact of gender difference on the 2-year clinical outcomes.
Methods
Finally, a total of 2403 eligible dyslipidemic AMI patients who underwent PCI with new-generation DES were enrolled and they were separated into two groups; the male group (n=1800) and the female group (n=603). The primary endpoint was major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), target lesion revascularization (TLR), and target vessel revascularization (TVR). The secondary endpoints were the incidence of the individual components of MACE and target vessel failure (TVF), a composite of death related to the target vessel, re-MI, or clinically driven TVR
Results
Two propensity score-matched (PSM) groups (422 pairs, n=844, C-statistic = 0.850) were generated. In the total study population, the cumulative incidences of MACE, all-cause death, re-MI, and TVF were significantly higher in the female group compared with the male group. However, after propensity score-matched (PSM) analysis, the cumulative incidences of MACE (HR, 0.971; 95% CI, 0.628–1.501; p=0.895), all-cause death (HR, 1.061; 95% CI, 0.536–2.100; p=0.865), re-MI (HR, 1.212; 95% CI, 0.433–2.907; p=0.813), and TVF (HR, 0.764; 95% CI, 0.474–1.229; p=0.267) were similar between the two groups. In addition, the cumulative incidences of cardiac death, TLR, TVR were not significantly different between the two groups (Table 1).
Outcomes Cumulative Events at 2-year (%) Hazard Ratio (95% CI) p value Male Female Log-rank Propensity score matched patients MACE 41 (10.4) 40 (10.3) 0.895 0.971 (0.628–1.501) 0.895 All-cause death 16 (4.0) 17 (4.2) 0.865 1.061 (0.536–2.100) 0.865 Cardiac death 13 (3.3) 9 (2.2) 0.391 0.691 (0.295–1.616) 0.393 Re-MI 8 (2.0) 9 (2.4) 0.813 1.212 (0.433–2.907) 0.813 TLR 7 (1.8) 6 (1.6) 0.781 0.857 (0.298–2.550) 0.781 TVR 16 (4.3) 10 (2.7) 0.236 0.623 (0.283–1.373) 0.241 TVF 39 (10.2) 30 (7.8) 0.265 0.764 (0.474–1.229) 0.267
Conclusion
The gender difference was not apparent in these dyslipidemic South Korean AMI patients who underwent PCI with new-generation DES during 2-year follow-up period.
Collapse
Affiliation(s)
- Y H Kim
- Kangwon National University School of Medicine, Chuncheon City, Korea (Republic of)
| | - A.-Y Her
- Kangwon National University School of Medicine, Chuncheon City, Korea (Republic of)
| | - M.-H Jeong
- Chonnam National University Hospital, Department of Cardiology, Gwangju, Korea (Republic of)
| | - B.-K Kim
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - S.-Y Lee
- Sanbon Hospital, Wonkwang University College of Medicine, Department of Cardiology, Gunpo, Korea (Republic of)
| | - S.-J Hong
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - D.-H Shin
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - C.-M Ahn
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - J.-S Kim
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - Y.-G Ko
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - D Choi
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - M.-K Hong
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| | - Y Jang
- Severance Cardiovascular Hospital, Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea (Republic of)
| |
Collapse
|
34
|
Park J, Kim J, Shin M, Choi D. P02.01 Analysis of Multimodal Intraoperative Monitoring During Intramedullary Spinal Ependymoma Surgery. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
To evaluate the validity of intraoperative somatosensory-evoked potential (SSEP) and motor-evoked potential (MEP) monitoring according to two different warning criteria for 6 months after intramedullary spinal ependymoma (IMSE) surgery.
MATERIAL AND METHODS
To evaluate the validity of intraoperative somatosensory-evoked potential (SSEP) and motor-evoked potential (MEP) monitoring according to two different warning criteria for 6 months after intramedullary spinal ependymoma (IMSE) surgery.
RESULTS
The success rates of SSEP and MEP monitoring were 84.9% and 83.7%, respectively. There was one indeterminate case in SSEP and six in MEP. All-or-none criterion in SSEP and MEP monitoring showed higher specificity, PPV, and DOR than 50% decline criterion during 6 months. During the follow up, 37 of 38 extremities (97.4%) and 21 of 29 extremities (72.4%) were observed the improvement of sensory and motor deficit, respectively. Seven indeterminate cases also showed good clinical outcomes. However, most patients remained some degree of neurologic deficit.
CONCLUSION
Many false positive and false negative results of SSEP and MEP monitoring occurred immediately postoperative period. All-or-none criterion was more beneficial for IMSE surgery than 50% decline criterion. This trend was maintained until 6 months after surgery.
Collapse
Affiliation(s)
- J Park
- The Catholic University of Korea, Incheon, Korea, Republic of
| | - J Kim
- The Catholic University of Korea, Incheon, Korea, Republic of
| | - M Shin
- The Catholic University of Korea, Incheon, Korea, Republic of
| | - D Choi
- The Catholic University of Korea, Incheon, Korea, Republic of
| |
Collapse
|
35
|
Mao N, Gao D, Hu W, Hieronymus H, Wang S, Lee YS, Lee C, Choi D, Gopalan A, Chen Y, Carver BS. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Mol Cancer Ther 2019; 18:1577-1586. [PMID: 31296553 DOI: 10.1158/1535-7163.mct-18-1386] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 05/02/2019] [Accepted: 07/01/2019] [Indexed: 11/16/2022]
Abstract
On the basis of our previous work defining the molecular rationale for combined targeting of the PI3K and AR pathways in PTEN loss prostate cancer, the first clinical trial was recently reported demonstrating a significant benefit for combination therapy in patients with metastatic prostate cancer. In this phase II trial, loss of PTEN was a biomarker predictive of response to combined AKT and AR inhibition. Given that PTEN loss prostate cancers are significantly enriched for ERG genomic rearrangements, we evaluated how the aberrant expression of ERG may impact response to PI3K/AR-targeted therapy. Here, we show that overexpression of ERG in the setting of Pten loss promotes resistance to combined PI3K and AR pathway inhibition with associated maintenance of AR target gene expression. Importantly, following AR knockout in the setting of ERG overexpression, there is maintenance of a subset of AR lineage-specific target genes, making AR dispensable in this context. This has important clinical implications as even in the setting of the androgen-regulated TMPRSS2:ERG genomic rearrangement, ERG expression is never abolished following AR inhibition and may allow for cell survival following AR (lineage)-targeted therapies.
Collapse
Affiliation(s)
- Ninghui Mao
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Dong Gao
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Wenhuo Hu
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Haley Hieronymus
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Shangqian Wang
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Young Sun Lee
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Cindy Lee
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Danielle Choi
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Anuradha Gopalan
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Yu Chen
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Brett S Carver
- Human Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. .,Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.,Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
36
|
Zhang Z, Karthaus W, Mota JM, Mu P, Wu C, Abida W, Linton E, Lee YS, Lee E, Mao N, Adams E, Choi D, Rathkopf DE, Carver B, Gopalan A, Jiang X, Watson P, Sawyers C. Abstract 111: Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite the improved clinical outcomes for patients with advanced prostate cancer due to the use of second generation antiandrogens, acquired drug resistance inevitably occurs and remains the major challenge for prostate cancer therapy. While several cell-autonomous mechanisms of drug resistance have been elucidated previously, for a large number of patients the mechanism of resistance remains unclear. Recent studies point to the importance of the tumor microenvironment (TME), and cancer associated fibroblasts (CAF) in the TME, in mediating tumor progression and resistance to therapy, but whether CAFs specifically contribute to antiandrogen resistance in prostate cancer is not known. Using a preclinical model that faithfully mimics the typical progression of patients on antiandrogen therapy, we found that antiandrogen resistance develops significantly faster when cells are grown in the presence of their cognate CAFs. By carrying out biochemical purification and mass spectrometry analysis, we identified NRG1 as a CAF secreted factor, and found that it can promote antiandrogen resistance in tumor cells, via activation of HER3 in the tumor. Importantly, blocking either NRG1 or HER3 can re-sensitize tumors to antiandrogen treatment in this model. Moreover, NRG1 expression is up-regulated in CAFs after antiandrogen exposure or in androgen deprivation condition. Clinically, increased stroma-NRG1 expression was observed in patients post androgen deprivation therapy but not in hormonally intact men. Taken together, this work has revealed a novel, NRG1-mediated non-cell autonomous mechanism of antiandrogen resistance in prostate cancer, and suggests that therapeutically targeting NRG1 in the setting of metastatic, antiandrogen-resistant prostate cancer with elevated NRG1 could provide significant benefit to patients.
Note: This abstract was not presented at the meeting.
Citation Format: Zeda Zhang, Wouter Karthaus, Jose Mauricio Mota, Ping Mu, Chao Wu, Wassim Abida, Eliot Linton, Young Sun Lee, Eugine Lee, Ninghui Mao, Elizabeth Adams, Danielle Choi, Dana E. Rathkopf, Brett Carver, Anuradha Gopalan, Xuejun Jiang, Philip Watson, Charles Sawyers. Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 111.
Collapse
Affiliation(s)
- Zeda Zhang
- 1Memorial Sloan-Kettering Cancer Ctr., New York, NY
| | | | | | - Ping Mu
- 2UT Southwestern Medical Center, Dallas, TX
| | - Chao Wu
- 1Memorial Sloan-Kettering Cancer Ctr., New York, NY
| | - Wassim Abida
- 1Memorial Sloan-Kettering Cancer Ctr., New York, NY
| | - Eliot Linton
- 1Memorial Sloan-Kettering Cancer Ctr., New York, NY
| | | | - Eugine Lee
- 1Memorial Sloan-Kettering Cancer Ctr., New York, NY
| | - Ninghui Mao
- 1Memorial Sloan-Kettering Cancer Ctr., New York, NY
| | | | | | | | - Brett Carver
- 1Memorial Sloan-Kettering Cancer Ctr., New York, NY
| | | | - Xuejun Jiang
- 1Memorial Sloan-Kettering Cancer Ctr., New York, NY
| | | | | |
Collapse
|
37
|
Won D, Choi D, Kim H. Clinical evaluation of the fourth-generation immunodiagnostic reagents “Elecsys HIV Duo” for screening HIV in specimens from Korean subjects. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
38
|
Taylor MH, Choi D, Fitzpatrick SM, Gunn KN. Characterisation of aluminium release by the enFlow® fluid‐warming system in crystalloids and blood products. Anaesthesia 2019; 74:1374-1380. [DOI: 10.1111/anae.14697] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/12/2019] [Indexed: 11/27/2022]
Affiliation(s)
- M. H. Taylor
- Department of Anaesthesia Middlemore Hospital Counties Manukau Health AucklandNew Zealand
| | - D. Choi
- Department of Anaesthesia Middlemore Hospital Counties Manukau Health AucklandNew Zealand
| | | | - K. N. Gunn
- Department of Anaesthesia and Peri‐operative Medicine Auckland District Health Board Auckland New Zealand
| |
Collapse
|
39
|
Lee S, Jung J, Choi J, Piao M, Choi D, Lee J. 323 Natural antioxidant products from peanuts sprouts and citron seed oils exhibit a potent anti-inflammatory activity in the oxazolone-induced contact dermatitis model in vivo. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Usher I, Choi D. P92 What is a benign notochordal cell tumour? J Neurol Neurosurg Psychiatry 2019. [DOI: 10.1136/jnnp-2019-abn.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
ObjectivesCharacteristics from a large systematic review.DesignThe first systematic review of benign notochordal cell tumours.SubjectsAll studies, in any language, published at any time, identified using specified search terms.MethodsPreferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).ResultsSo-called benign notochordal cell tumours exhibited the following features: pain was the sole presenting symptom in 37/81 (45.7%) and neurological deficit in 36/81 (44.4%). Incidental discovery upon imaging was reported in 8/81 (9.9%). Radiologically, lesions were small, (≤30 millimetres at their maximum diameter) in 57/65 (87.7%), hypointense on T1 sequences and hyperintense on T2 sequences on magnetic resonance imaging (106/130; 81.5%), did not enhance following contrast administration (62/74; 83.8%) and were non-lytic (80/160; 50.0%). Histologically, these tumours lacked myxoid matrix (66/84; 78.6%) and nuclear atypia (100/112; 89.3%). In those managed conservatively, follow up was between 8.5 and 120 months. Most were stable at follow up (22/25; 88.0%), one lesion grew (4.0%), one patient died of an unrelated cause (4.0%) and outcome was not stated in one case (4.0%).ConclusionsBNCTs exhibit a spectrum of features, none of which are pathognomonic and diagnosis is subjective. The majority of reports describe small, non-progressive, non-lytic lesions that lack contrast enhancement, intercellular myxoid matrix and nuclear atypia. They are nevertheless difficult to distinguish from small chordomas.
Collapse
|
41
|
Bartlett RD, Phillips JB, Choi D. P25 Hydrogel systems to enhance the delivery of cell therapy for traumatic spinal cord injury. J Neurol Neurosurg Psychiatry 2019. [DOI: 10.1136/jnnp-2019-abn.100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
ObjectivesCell therapies are an emerging therapeutic approach for spinal cord injury. We assessed the survival and phenotype of olfactory ensheathing cells (OECs) in hydrogel delivery systems suitable for clinical use.DesignLaboratory study.MethodsCell survival in different formulations of collagen and fibrin hydrogels was assessed using Syto 9 and propidium iodide. The proportion of cells staining positive for a key repair marker (p75NTR) was also quantified using immunocytochemistry and fluorescence microscopy.ResultsThere were significant differences in OEC survival between the various collagen and fibrin hydrogel formulations tested (p<0.001 one-way ANOVA, n=17). 10% v/v fibrin conferred the best cell survival with 85% of OECs remaining alive. Incorporating OECs into collagen hydrogels promoted the highest proportion of p75NTR immunopositive cells (78%) and this was significantly higher than both fibrin hydrogels and traditional monolayer culture (53% and 20%, respectively, p<0.0001 one-way ANOVA, n=24).ConclusionsCollagen and fibrin hydrogels both have the potential to enhance the delivery, survival and retention of transplanted OECs for spinal cord repair. Both materials are clinically scalable, promote favourable OEC survival and have the potential to increase the proportion of cells expressing a key repair marker (p75NTR). Optimised hydrogel delivery systems may provide a valuable approach to improve the delivery of OECs for spinal cord repair in the future.
Collapse
|
42
|
Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL. GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance. eLife 2019; 8:e41913. [PMID: 30644358 PMCID: PMC6336405 DOI: 10.7554/elife.41913] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 12/27/2018] [Indexed: 01/22/2023] Open
Abstract
Genomic amplification of the androgen receptor (AR) is an established mechanism of antiandrogen resistance in prostate cancer. Here, we show that the magnitude of AR signaling output, independent of AR genomic alteration or expression level, also contributes to antiandrogen resistance, through upregulation of the coactivator GREB1. We demonstrate 100-fold heterogeneity in AR output within human prostate cancer cell lines and show that cells with high AR output have reduced sensitivity to enzalutamide. Through transcriptomic and shRNA knockdown studies, together with analysis of clinical datasets, we identify GREB1 as a gene responsible for high AR output. We show that GREB1 is an AR target gene that amplifies AR output by enhancing AR DNA binding and promoting EP300 recruitment. GREB1 knockdown in high AR output cells restores enzalutamide sensitivity in vivo. Thus, GREB1 is a candidate driver of enzalutamide resistance through a novel feed forward mechanism.
Collapse
Affiliation(s)
- Eugine Lee
- Human Oncology and Pathogenesis ProgramMemorial Sloan Kettering Cancer CenterNew YorkUnited States
| | - John Wongvipat
- Human Oncology and Pathogenesis ProgramMemorial Sloan Kettering Cancer CenterNew YorkUnited States
| | - Danielle Choi
- Human Oncology and Pathogenesis ProgramMemorial Sloan Kettering Cancer CenterNew YorkUnited States
| | - Ping Wang
- Department of GeneticsAlbert Einstein College of MedicineNew YorkUnited States
| | - Young Sun Lee
- Human Oncology and Pathogenesis ProgramMemorial Sloan Kettering Cancer CenterNew YorkUnited States
| | - Deyou Zheng
- Department of GeneticsAlbert Einstein College of MedicineNew YorkUnited States
- Department of NeurologyAlbert Einstein College of MedicineNew YorkUnited States
- Department of NeuroscienceAlbert Einstein College of MedicineNew YorkUnited States
| | - Philip A Watson
- Human Oncology and Pathogenesis ProgramMemorial Sloan Kettering Cancer CenterNew YorkUnited States
| | - Anuradha Gopalan
- Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUnited States
| | - Charles L Sawyers
- Human Oncology and Pathogenesis ProgramMemorial Sloan Kettering Cancer CenterNew YorkUnited States
- Howard Hughes Medical InstituteChevy ChaseUnited States
| |
Collapse
|
43
|
Kim J, Choi D, Paik E, Lee J, Bae D, Kim T. Laparoendoscopic Single Site Myomectomy with Uterine Artery Ligation via Retroperitoneal Approach is Feasible for Huge Uterine Myoma. J Minim Invasive Gynecol 2018. [DOI: 10.1016/j.jmig.2018.09.583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Davis C, McCain J, Israel H, Choi D, Behrman D, Grewal N. Arthroscopy of Temporomandibular Joint Prosthesis, Preliminary Experience and Results. J Oral Maxillofac Surg 2018. [DOI: 10.1016/j.joms.2018.06.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Chennakrishnaiah S, Meehan B, D'Asti E, Montermini L, Lee TH, Karatzas N, Buchanan M, Tawil N, Choi D, Divangahi M, Basik M, Rak J. Leukocytes as a reservoir of circulating oncogenic DNA and regulatory targets of tumor-derived extracellular vesicles. J Thromb Haemost 2018; 16:1800-1813. [PMID: 29971917 DOI: 10.1111/jth.14222] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Indexed: 12/11/2022]
Abstract
Essentials Tumor-bearing mice were employed to follow oncogenic HRAS sequences in plasma, and blood cells. Cancer DNA accumulated in leukocytes above levels detected in exosomes, platelets and plasma. Extracellular vesicles and nucleosomes are required for uptake of tumor DNA by leukocytes. Uptake of tumor-derived extracellular vesicles by leukocytes triggers coagulant phenotype. SUMMARY Background Tumor-derived extracellular vesicles (EVs) and free nucleosomes (NSs) carry into the circulation a wealth of cancer-specific, bioactive and poorly understood molecular cargoes, including genomic DNA (gDNA). Objective Here we investigated the distribution of extracellular oncogenic gDNA sequences (HRAS and HER2) in the circulation of tumor-bearing mice. Methods and Results Surprisingly, circulating leukocytes (WBCs), especially neutrophils, contained the highest levels of mutant gDNA, which exceeded the amount of this material recovered from soluble fractions of plasma, circulating EVs, platelets, red blood cells (RBCs) and peripheral organs, as quantified by digital droplet PCR (ddPCR). Tumor excision resulted in disappearance of the WBC-associated gDNA signal within 2-9 days, which is in line with the expected half-life of these cells. EVs and nucleosomes were essential for the uptake of tumor-derived extracellular DNA by neutrophil-like cells and impacted their phenotype. Indeed, the exposure of granulocytic HL-60 cells to EVs from HRAS-driven cancer cells resulted in a selective increase in tissue factor (TF) procoagulant activity and interleukin 8 (IL-8) production. The levels of circulating thrombin-antithrombin complexes (TAT) were markedly elevated in mice harboring HRAS-driven xenografts. Conclusions Myeloid cells may represent a hitherto unrecognized reservoir of cancer-derived, EV/NS-associated oncogenic gDNA in the circulation, and a possible novel platform for liquid biopsy in cancer. In addition, uptake of this material alters the phenotype of myeloid cells, induces procoagulant and proinflammatory activity and may contribute to systemic effects associated with cancer.
Collapse
Affiliation(s)
- S Chennakrishnaiah
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| | - B Meehan
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| | - E D'Asti
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| | - L Montermini
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| | - T-H Lee
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| | - N Karatzas
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| | - M Buchanan
- Department of Oncology and Surgery, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
| | - N Tawil
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| | - D Choi
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| | - M Divangahi
- Department of Medicine, Department of Microbiology and Immunology, Department of Pathology, McGill International TB Centre, McGill University Health Centre, Meakins-Christie Laboratories, Montreal, QC, Canada
| | - M Basik
- Department of Oncology and Surgery, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
| | - J Rak
- Research Institute of the McGill University Health Centre, Glen Site, McGill University, Montreal, QC, Canada
| |
Collapse
|
46
|
Irani M, Parrella A, O'Neill C, Lu V, Choi D, Rosenwaks Z, Palermo G. In vitro neospermatogenesis of human induced pluripotent stem cells. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.1052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
47
|
Lu V, Parrella A, Choi D, Irani M, O'Neill C, Rosenwaks Z, Palermo G. Differentiating mouse-induced pluripotent stem cells into male germ cells through embryoid bodies. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.1050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
|
49
|
Parrella A, Choi D, Keating D, Rosenwaks Z, Palermo G. A microfluidic device for selecting the most progressively motile spermatozoa yields a higher rate of euploid embryos. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.955] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Lee SH, Kim K, Lee CJ, Oh J, Park S, Kang SM, Choi D. P5391Statin and clinical outcome in patients >75 years without atherosclerotic cardiovascular disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- S.-H Lee
- Yonsei University College of Medicine, Cardiology, Internal Medicine, Seoul, Korea Republic of
| | - K Kim
- Yonsei University College of Medicine, Cardiology, Internal Medicine, Seoul, Korea Republic of
| | - C J Lee
- Yonsei University College of Medicine, Cardiology, Internal Medicine, Seoul, Korea Republic of
| | - J Oh
- Yonsei University College of Medicine, Cardiology, Internal Medicine, Seoul, Korea Republic of
| | - S Park
- Yonsei University College of Medicine, Cardiology, Internal Medicine, Seoul, Korea Republic of
| | - S.-M Kang
- Yonsei University College of Medicine, Cardiology, Internal Medicine, Seoul, Korea Republic of
| | - D Choi
- Yonsei University College of Medicine, Cardiology, Internal Medicine, Seoul, Korea Republic of
| |
Collapse
|